Deal is worth $26 a share for specialist in hepatitis C treatments
Pharmaceutical giant Bristol-Myers Squibb is purchasing Inhibitex Inc., a specialist in hepatitis C treatments, in a cash tender offer for $2.5 billion.
In a deal announced late Saturday, Bristol-Myers will pay $26 a share for Inhibitex, based in Alpharetta, Ga., a suburb of Atlanta.
Inhibitex shares ended Friday trading at $9.87, up 24 cents, or 2.5%. New York-based Bristol-Myers was up marginally to $34.22.
While Inhibitex describes itself as dedicated to developing treatments for all serious infections, it’s now focused primarily on the treatment of hepatitis C. Its lead product in that realm is called INX-189, an oral treatment which it says has exhibited potent antiviral activity. INX-189 is in Phase II development.
“This transaction puts INX-189 and the company’s other infectious disease assets in the hands of an organization that can more optimally develop them, and which believes as strongly as we do in INX-189’s potential in the treatment of chronic [hepatitis C],” Russell Plumb, Inhibitex’s chief executive said in a prepared statement.
“There is significant unmet medical need in hepatitis C. This acquisition represents an important investment in the long-term growth of the company,” Lamberto Andreotti, Bristol-Myers Squibb’s chief executive said in the same statement.
Bristol-Myers said the deal should be dilutive to earnings through 2016, with an impact of 4 cents a share in 2012 and 5 cents a share in 2013.
Have you ever considered iaddng more videos to your blog posts to keep the readers more entertained? I mean I just read through the entire article of yours and it was quite good but since I’m more of a visual learner,I found that to be more helpful well let me know how it turns out! I love what you guys are always up too. Such clever work and reporting! Keep up the great works guys I’ve added you guys to my blogroll. This is a great article thanks for sharing this informative information.. I will visit your blog regularly for some latest post.